Q-omics provides the consensus-scored GCOM1 profile across patient tissues and cancer cell-line models. GCOM1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, GCOM1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GCOM1 RNA expression shows 17,627 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, KIRC, and TGCT as cancer lineages where GCOM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCOM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCOM1 survival associations across molecular data types. GCOM1 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCOM1 RNA expression–survival associations across cancer types. High GCOM1 expression shows unfavorable associations in CESC, LUSC, LGG, OV and UCEC, but favorable associations in BRCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for GCOM1 RNA expression.
This table summarizes GCOM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GCOM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCOM1 shows lower tumor expression in KIRC, LUAD, COAD, HNSC, KIRP and THCA. The KIRC box plot shows higher GCOM1 RNA expression in normal versus tumor tissue (log2 FC = −0.612, t-test p < 0.001).
This table shows molecular features associated with GCOM1 in patient tissues and cancer cell lines. In patient samples, GCOM1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GCOM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
